Shanthi Narla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shanthi Narla has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Iltefat H. Hamzavi
Henry Ford Medical Center, Detroit, USA
7 shared publications - Alexis B. Lyons
Department of Dermatology Henry Ford Health System Detroit MI USA
4 shared publications - Henry W. Lim
International League of Dermatological Societies (ILDS) London UK
4 shared publications - David Md Ozog
Department of Dermatology, Henry Ford Health, Detroit, Michigan
3 shared publications - Jonathan Ian Silverberg
Department of Dermatology, The George Washington University School of Medicine and Health Sciences , Washington, DC
2 shared publications A. F. Nahhas
Department of Dermatology Beaumont Health‐Farmington Hills Farmington Hills MI USA
1 shared publication
Latest Publications
- 1 November 2025
- Published by SAGE Publications in Dermatitis®
- Vol. 36 (6) , 583-600
What Does Long-Term Control in Atopic Dermatitis Look Like?
What defines long-term control in atopic dermatitis (AD) and why is it difficult to measure in AD? Why does long-term control matter? Herein, we critically examine these questions along with the clinical rationale, approaches for assessing long-term control in clinical practice, potential mechanistic underpinnings for AD long-term control, and evidence for long-term control with current systemic AD treatments. Currently, there is limited consensus on how to define flares and long-term control due to AD’s heterogeneous nature, and AD being a disorder largely defined by patients’ individual experience. An important part of long-term control is disease modification, which is made up of the impact on the disease itself and also its impact on AD’s associated comorbidities. By focusing on the multiple facets of long-term control, possible deep/long-term remission or even therapy open-access remission may be achieved. While there is some research currently available on the long-term efficacy of current AD therapies, larger studies with longer follow-up periods are needed to adequately determine if reduced dosing can be applied to AD patients who have achieved deep/long-term remission. Future directions in AD may involve developing new therapies that target the innate and adaptive immune systems to bring about disease modification.
- 1 November 2025
- Published by SAGE Publications in Dermatitis®
- Vol. 36 (6) , 583-600
What Does Long-Term Control in Atopic Dermatitis Look Like?
What defines long-term control in atopic dermatitis (AD) and why is it difficult to measure in AD? Why does long-term control matter? Herein, we critically examine these questions along with the clinical rationale, approaches for assessing long-term control in clinical practice, potential mechanistic underpinnings for AD long-term control, and evidence for long-term control with current systemic AD treatments. Currently, there is limited consensus on how to define flares and long-term control due to AD’s heterogeneous nature, and AD being a disorder largely defined by patients’ individual experience. An important part of long-term control is disease modification, which is made up of the impact on the disease itself and also its impact on AD’s associated comorbidities. By focusing on the multiple facets of long-term control, possible deep/long-term remission or even therapy open-access remission may be achieved. While there is some research currently available on the long-term efficacy of current AD therapies, larger studies with longer follow-up periods are needed to adequately determine if reduced dosing can be applied to AD patients who have achieved deep/long-term remission. Future directions in AD may involve developing new therapies that target the innate and adaptive immune systems to bring about disease modification.
- 13 August 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (2) , 319-324
Assessment of inter‐rater reliability of clinical hidradenitis suppurativa outcome measures using ultrasonography
Background Hidradenitis suppurativa (HS) staging and severity is typically based upon physical examination findings which can result in misclassification of severity based on subclinical disease activity and significant variation between healthcare providers. Ultrasound (US) is an objective tool to help evaluate subclinical disease and more accurately classify severity of disease. The objective of this study was to evaluate inter-rater reliability in HS disease severity assessment using clinical and US techniques. Methods Twenty subjects underwent clinical evaluation of HS using clinical outcome measures including Hurley, Sartorius, HS Physician Global Assessment (HS-PGA), and Hidradenitis Suppurativa Clinical Response (HiSCR) independently by two physicians. US was subsequently performed, and clinical assessments were repeated. Intra-class correlation coefficients (ICC) were obtained to evaluate inter-rater agreement of each outcome measure before and after US. Results Pre- to post-US improvement in ICC was seen with the Sartorius, HiSCR nodule and abscess count, and HiSCR draining fistula count. The scores went from having “good” rater agreement for Sartorius and HiSCR nodule and abscess count and “poor” rater agreement for HiSCR draining fistula count to “excellent” rater agreement amongst these scores. Conclusions US improved inter-rater agreement and should be used in conjunction with physical examination findings to evaluate disease severity to ensure uniform staging.
- 13 August 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (2) , 319-324
Assessment of inter‐rater reliability of clinical hidradenitis suppurativa outcome measures using ultrasonography
Background Hidradenitis suppurativa (HS) staging and severity is typically based upon physical examination findings which can result in misclassification of severity based on subclinical disease activity and significant variation between healthcare providers. Ultrasound (US) is an objective tool to help evaluate subclinical disease and more accurately classify severity of disease. The objective of this study was to evaluate inter-rater reliability in HS disease severity assessment using clinical and US techniques. Methods Twenty subjects underwent clinical evaluation of HS using clinical outcome measures including Hurley, Sartorius, HS Physician Global Assessment (HS-PGA), and Hidradenitis Suppurativa Clinical Response (HiSCR) independently by two physicians. US was subsequently performed, and clinical assessments were repeated. Intra-class correlation coefficients (ICC) were obtained to evaluate inter-rater agreement of each outcome measure before and after US. Results Pre- to post-US improvement in ICC was seen with the Sartorius, HiSCR nodule and abscess count, and HiSCR draining fistula count. The scores went from having “good” rater agreement for Sartorius and HiSCR nodule and abscess count and “poor” rater agreement for HiSCR draining fistula count to “excellent” rater agreement amongst these scores. Conclusions US improved inter-rater agreement and should be used in conjunction with physical examination findings to evaluate disease severity to ensure uniform staging.
- Open Access
- 28 May 2021
- Published by Springer Nature in Current Dermatology Reports
- Vol. 10 (3) , 77-88
Management of atopic dermatitis in the inpatient setting
- 28 May 2021
- Published by Springer Nature in Current Dermatology Reports
- Vol. 10 (3) , 77-88
Open AccessManagement of atopic dermatitis in the inpatient setting
- Open Access
- 1 February 2021
- Published by Elsevier in JAAD Case Reports
- Vol. 8, 77-79
Infusion reaction to infliximab biosimilar after transitioning from infliximab
- 1 February 2021
- Published by Elsevier in JAAD Case Reports
- Vol. 8, 77-79
Open AccessInfusion reaction to infliximab biosimilar after transitioning from infliximab
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 84 (1) , 120-129
Proceeding report of the Fourth Symposium on Hidradenitis Suppurativa Advances 2019
- 1 January 2021
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 84 (1) , 120-129
Open AccessProceeding report of the Fourth Symposium on Hidradenitis Suppurativa Advances 2019
- Open Access
- 1 November 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 100, 224-229
The effect of ultraviolet C radiation against different N95 respirators inoculated with SARS-CoV-2
- 1 November 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 100, 224-229
Open AccessThe effect of ultraviolet C radiation against different N95 respirators inoculated with SARS-CoV-2
- 7 September 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (6) , 1004-1013
Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils
Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. The disorder is characterized by comedones, painful inflammatory nodules, abscesses, dermal tunnels, and scarring, with a predilection for intertriginous areas of the body (axillae, inguinal, and anogenital regions). Recruitment of neutrophils to HS lesion sites may play an essential role in the development of the painful inflammatory nodules and abscesses that characterize the disease. This is a review of the major mediators involved in the recruitment of neutrophils to sites of active inflammation including bacterial components (endotoxins, exotoxins, capsule fragments, etc.), the complement pathway anaphylatoxins C3a and C5a, tumor necrosis factor‐alpha (TNF‐ α), interleukin 17 (IL‐17), interleukin 8 (CXCL8/IL‐8), interleukin 36 (IL‐36), interleukin 1 (IL‐1), lipocalin‐2, leukotriene B4 (LTB4), platelet‐activating factor, kallikrein, matrix metalloproteinases (MMPs), and myeloperoxidase inhibitors. Pharmacologic manipulation of the various pathways involved in the process of neutrophil recruitment and activation could allow for successful control and stabilization of HS lesions and the remission of active, severe flares.
- 7 September 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (6) , 1004-1013
Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils
Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. The disorder is characterized by comedones, painful inflammatory nodules, abscesses, dermal tunnels, and scarring, with a predilection for intertriginous areas of the body (axillae, inguinal, and anogenital regions). Recruitment of neutrophils to HS lesion sites may play an essential role in the development of the painful inflammatory nodules and abscesses that characterize the disease. This is a review of the major mediators involved in the recruitment of neutrophils to sites of active inflammation including bacterial components (endotoxins, exotoxins, capsule fragments, etc.), the complement pathway anaphylatoxins C3a and C5a, tumor necrosis factor‐alpha (TNF‐ α), interleukin 17 (IL‐17), interleukin 8 (CXCL8/IL‐8), interleukin 36 (IL‐36), interleukin 1 (IL‐1), lipocalin‐2, leukotriene B4 (LTB4), platelet‐activating factor, kallikrein, matrix metalloproteinases (MMPs), and myeloperoxidase inhibitors. Pharmacologic manipulation of the various pathways involved in the process of neutrophil recruitment and activation could allow for successful control and stabilization of HS lesions and the remission of active, severe flares.
- Open Access
- 26 August 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 1049
The most recent advances in understanding and managing hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. HS has a significant negative impact on both the quality of life (QOL) of patients affected by this disease as well as family members and caregivers. However, the pathogenesis of HS is multifactorial and still remains to be fully elucidated, which makes the development of treatments difficult. The last 10 years have seen a surge in HS research, and many new findings have come to light, yet much more remains to be elucidated. Physicians must employ a multidisciplinary approach to maximally address all facets of HS. Clinical characteristics of the disease that differ between females and males as well as across different races and ethnic groups must be considered. Targeted topical, oral, and injectable therapies continue to be developed for HS as a greater understanding of the pathogenesis is reached. However, randomized controlled trials regarding dietary factors that may contribute to HS are needed to meet our patients’ growing concerns and questions about the role of diet in HS pathogenesis. Finally, improved outcome measures are needed to standardize HS severity and grading between physicians and clinical trials, and a more diverse representation of HS populations is needed in clinical trials.
- 26 August 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 1049
Open AccessThe most recent advances in understanding and managing hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. HS has a significant negative impact on both the quality of life (QOL) of patients affected by this disease as well as family members and caregivers. However, the pathogenesis of HS is multifactorial and still remains to be fully elucidated, which makes the development of treatments difficult. The last 10 years have seen a surge in HS research, and many new findings have come to light, yet much more remains to be elucidated. Physicians must employ a multidisciplinary approach to maximally address all facets of HS. Clinical characteristics of the disease that differ between females and males as well as across different races and ethnic groups must be considered. Targeted topical, oral, and injectable therapies continue to be developed for HS as a greater understanding of the pathogenesis is reached. However, randomized controlled trials regarding dietary factors that may contribute to HS are needed to meet our patients’ growing concerns and questions about the role of diet in HS pathogenesis. Finally, improved outcome measures are needed to standardize HS severity and grading between physicians and clinical trials, and a more diverse representation of HS populations is needed in clinical trials.
- Open Access
The Effect of Ultraviolet C Radiation Against SARS-CoV-2 Inoculated N95 Respirators
Since March 31 st , 2020, during the height of the pandemic, we have decontaminated thousands of 3M 1860 respirators with Ultraviolet C (UVC) for our frontline workers. There is no published peer-reviewed data regarding the dose required to effectively disinfect SARS-CoV-2 on N95 filtering facepiece respirators (FFRs). Four different locations (facepiece and strap) on 5 different N95 FFR models (3M 1860, 8210, 8511, 9211; Moldex 1511) were inoculated with a 10 μL drop of SARS-CoV-2 viral stock (8 × 10 7 TCID 50 /mL). The outside-facing and wearer-facing surfaces of the respirators were each irradiated with a dose of 1.5 J/cm 2 UVC (254 nm). Viable SARS-CoV-2 was quantified by a median tissue culture infectious dose assay (TCID 50 ). UVC delivered using a dose of 1.5 J/cm 2 , to each side, was an effective method of decontamination for the facepieces of 3M 1860 and Moldex 1511, and for the straps of 3M 8210 and the Moldex 1511. This dose is an appropriate decontamination method to facilitate reuse of respirators for healthcare personnel when applied to certain models/materials. Increasing the dose may improve decontamination for the other models and straps; however, UVC radiation can degrade certain polymers in a dose dependent manner, and the effects may vary greatly between different models. Therefore, fit-testing of UVC decontaminated respirators must be performed each time a new model and/or dose is introduced into the healthcare system.
Open AccessThe Effect of Ultraviolet C Radiation Against SARS-CoV-2 Inoculated N95 Respirators
Since March 31 st , 2020, during the height of the pandemic, we have decontaminated thousands of 3M 1860 respirators with Ultraviolet C (UVC) for our frontline workers. There is no published peer-reviewed data regarding the dose required to effectively disinfect SARS-CoV-2 on N95 filtering facepiece respirators (FFRs). Four different locations (facepiece and strap) on 5 different N95 FFR models (3M 1860, 8210, 8511, 9211; Moldex 1511) were inoculated with a 10 μL drop of SARS-CoV-2 viral stock (8 × 10 7 TCID 50 /mL). The outside-facing and wearer-facing surfaces of the respirators were each irradiated with a dose of 1.5 J/cm 2 UVC (254 nm). Viable SARS-CoV-2 was quantified by a median tissue culture infectious dose assay (TCID 50 ). UVC delivered using a dose of 1.5 J/cm 2 , to each side, was an effective method of decontamination for the facepieces of 3M 1860 and Moldex 1511, and for the straps of 3M 8210 and the Moldex 1511. This dose is an appropriate decontamination method to facilitate reuse of respirators for healthcare personnel when applied to certain models/materials. Increasing the dose may improve decontamination for the other models and straps; however, UVC radiation can degrade certain polymers in a dose dependent manner, and the effects may vary greatly between different models. Therefore, fit-testing of UVC decontaminated respirators must be performed each time a new model and/or dose is introduced into the healthcare system.
- 28 April 2020
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 36 (4) , 324-325
The importance of the minimum dosage necessary for UVC decontamination of N95 respirators during the COVID‐19 pandemic
- 28 April 2020
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 36 (4) , 324-325
The importance of the minimum dosage necessary for UVC decontamination of N95 respirators during the COVID‐19 pandemic